Generic Bonjesta Availability
Last updated on Nov 6, 2024.
Bonjesta is a brand name of doxylamine/pyridoxine, approved by the FDA in the following formulation(s):
BONJESTA (doxylamine succinate; pyridoxine hydrochloride - tablet, extended release;oral)
-
Manufacturer: DUCHESNAY
Approval date: November 7, 2016
Strength(s): 20MG;20MG [RLD]
Has a generic version of Bonjesta been approved?
No. There is currently no therapeutically equivalent version of Bonjesta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bonjesta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Patent 9,089,489
Issued: July 28, 2015
Inventor(s): Vranderick Manon & St-Onge Jean-Luc & Gedeon Christelle & Gallo Michele & Gervais Éric
Assignee(s): Duchesnay Inc.A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
Patent expiration dates:
- February 18, 2033✓✓
- February 18, 2033
-
Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Patent 9,375,404
Issued: June 28, 2016
Inventor(s): Vranderick Manon & St-Onge Jean-Luc & Gedeon Christelle & Gallo Michele & Gervais Éric
Assignee(s): Duchesnay Inc.A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
Patent expiration dates:
- February 18, 2033✓✓
- February 18, 2033
-
Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Patent 9,526,703
Issued: December 27, 2016
Inventor(s): Vranderick Manon & St-Onge Jean-Luc & Gallo Michele & Gervais Éric
Assignee(s): Duchesnay Inc.A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed.
Patent expiration dates:
- February 18, 2033✓✓
- February 18, 2033
-
Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Patent 9,937,132
Issued: April 10, 2018
Inventor(s): Vranderick Manon & St-Onge Jean-Luc & Gedeon Christelle & Gallo Michele & Gervais Éric
Assignee(s): DUCHESNAY INC.A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
Patent expiration dates:
- February 18, 2033✓✓
- February 18, 2033
More about Bonjesta (doxylamine / pyridoxine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (33)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antiemetics
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
